1. NAFLD: A pretransplant and post-transplant conundrum. Rodas FV and N Shankar, Clinical Liver Disease. 21(4): p. 93-98, April 2023. DOI:10.1097/CLD.0000000000000021
  2. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN; NN9931-4492 investigators. Lancet Gastroenterol Hepatol. 2023 Mar 16:S2468-1253(23)00068-7. doi: 10.1016/S2468-1253(23)00068-7. 
  3. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, Goh GBB, Huang JF, Serra C, Andreone P, Chen YC, Hsia SH, Ratziu V, Aizenberg D, Tobita H, Sheikh AM, Vierling JM, Kim YJ, Hyogo H, Tai D, Goodman Z, Schaefer F, Carbarns IRI, Lamle S, Martic M, Naoumov NV, Brass CA. Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8. 
  4. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777. 
  5. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. doi: 10.1016/S2468-1253(22)00347-8.
  6. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3. doi: 10.1016/j.cgh.2021.12.044. 
  7. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Feld JJ, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, Han SH, Dieterich D, Giard JM, De La Rosa G, Ahmad A, Luo E, Conery AL, Adda N. Antivir Ther. 2022 Dec;27(6):13596535221127848. doi: 10.1177/13596535221127848.
  8. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. J Hepatol. 2023 Mar;78(3):479-492. doi: 10.1016/j.jhep.2022.10.023. 
  9. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. Lawitz EJ, Li KW, Nyangau E, Field TJ, Chuang JC, Billin A, Wang L, Wang Y, Huss RS, Chung C, Subramanian GM, Myers RP, Hellerstein MK. J Lipid Res. 2022 Sep;63(9):100250. doi: 10.1016/j.jlr.2022.100250.
  10. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. Sulkowski M, Telep LE, Colombo M, Durand F, Reddy KR, Lawitz E, Bourlière M, Cheinquer N, Scherbakovsky S, Ni L, Force L, Ramroth H, Gaggar A, Chokkalingam AP, Sise ME.  Aliment Pharmacol Ther. 2022 May;55(9):1169-1178. doi: 10.1111/apt.16830. 
  11. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. Wong VW, Tak WY, Goh GBB, Cheng PN, Lawitz EJ, Younossi ZM, Vuppalanchi R, Younes Z, Alkhouri N, Wang L, Liu J, Kersey K, Myers RP, Harrison SA, Goodman Z, Trauner M, Romero-Gomez M, Anstee QM, Nguyen MH, Okanoue T. Clin Gastroenterol Hepatol. 2023 Jan;21(1):90-102.e6. doi: 10.1016/j.cgh.2022.01.015. 
  12. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. 
  13. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED. Hepatology. 2022 Apr;75(4):912-923. doi: 10.1002/hep.32181. 
  14. Wong VW, Tak WY, Goh GBB, Cheng PN, Lawitz EJ et al, Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic whites in the STELLAR trials. Clin Gastroenterol Hepatol. 2022 Jan 21:S1542-3565(22)00069-6. doi: 10.1016/j.cgh.2022.01.015
  15. Lawitz EJ, Bhandari BP, Ruane PJ et al, Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2022 Jan 6:S1542-3565(22) 00002-7. doi: 10.1016/j.cgh.2021.12.044.
  16. Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021 Nov 3: S0168-8278 (21)02155-3. doi: 10.1016/j.jhep.2021.10.018.
  17. Ratziu V, de Guevara L, Safadi R, Poordad F, ARREST investigator study group, Sanyal AJ. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021 Oct; 27(10): 1825-1835: 10.1038/s41591-021-01495-3.
  18. Sanyal AJ, Anstee QM, Trauner M, Lawitz EL, et al, Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
  19. Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
  20. Zamor PJ, Brown A…Lawitz E, Jacobson IM, High sustained virologic response rates of glecaprevir/pibrentasvir in patients with dosing interruption or suboptimal adherence. Am J Gastroenterol. 2021 Sep 1; 116(9): 1896-1904. doi: 10.14309/ajg.0000000000001332.
  21. Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 2021 Aug; 27(8): 1191-1202. doi: 10.1002/lt.26072.
  22. Harrison SA, Bashir MR,…Lawitz EJ et al., A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021 Jul; 75(1): 25-33. doi: 10.1016/j.jhep.2021.01.047. Epub 2021 Feb 11.
  23. Taylor-Weiner A, Pokkalla H, …Lawitz EJ, A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology. 2021 Jul; 74(1): 133-147.
  24. Younossi ZM, Anstee QM,…Lawitz EJ et al, The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology. 2021 Apr; 160(5): 1608-1619.e13.
  25. Younossi ZM, Wong VW, Anstee QM,…Lawitz EJ, et al., Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes. Hepatol Commun. 2020 Aug 28; 4(11): 1637-1650.
  26. Alkhouri N, Reddy GK, Lawitz E, Oligonucleotide-based therapeutics: an emerging strategy for the treatment of chronic liver diseases. Hepatology. 2021 Apr; 73(4): 1581-1593.
  27. Lawitz E, Landis CS, Flamm SL et al., Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomized, open-label study. Lancet Gastroenterol Hepatol. 2020 Oct; 5(10): 918-926.
  28. Harrison SA, Wong VW, Lawitz EJ et al., Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020 Jul; 73(1): 26-39.
  29. Patel K, Harrison SA, Lawitz EJ, et al., Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled study. Hepatology. 2020 Jul; 72(1): 58-71.
  30. Garcia-Tsao G, Bosch J, Lawitz EJ, et al., Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020 May; 72(5): 885-895.
  31. Lawitz E, Flisiak R et al., Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020 May; 40(5): 1032-1041.
  32. Bajaj JS, Bloom PP,….Lawitz E, Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice. Am J Gastroenterol. 2020 May; 115(5): 783-785.
  33. Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Ngugen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentavir in patients with HCV genotype 5/6: An integrated analysis of Phase 2/3 studies. Liver Int. 2020 May 23. doi: 10.1111/liv.14535. Online ahead of print.
  34. Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep. 2020 Feb 22;3(2): e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.
  35. Singh A, Gosai F, Siddiqui MT, Gupta M, Lopez R, Lawitz E, Poordad F, Carey W, McCullough A, Alkhouri N. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients with Type-2 Diabetes with Biopsy-proven Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol. 2020 Mar 11. doi: 10.1097/MCG.0000000000001339. [Epub ahead of print] PMID:32168133
  36. Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol. 2020 Jan 25; 2020:5421632. doi: 10.1155/2020/5421632. eCollection 2020. PMID:32047671
  37. Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]
  38. Elsaid MI, Rustgi VK, Loo N, Aggarwal K, Li-McLeod J, Niu X, Poordad F. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease. J Med Econ. 2020 Apr;23(4):378-385. doi: 10.1080/13696998.2019.1699563. Epub 2019 Dec 15.
  39. Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol. 2019 Oct 27;11(10):710-718. doi: 10.4254/wjh.v11.i10.710.
  40. Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol. 2019;25(18):2229-2239.
  41. Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore). 2019;98(26): e16254
  42. Poordad F, Sedghi S, Pockros PJ, Ravendhran N, Reindollar R, Lucey MR, Epstein M, Bank L, Bernstien D, Trinh R, Krishnan P, Polepally AR, Unnebrink K, Martinez M, Nelson DR. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. J Viral Hepat. 2019;26(8):1027-1030.
  43. Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, Hwang P, Caro L, Robertson M, Charles ED, Platt H. Elbasvir/Grazoprevir in People with Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. Clin Transl Gastroenterol. 2019 Apr; 10(4): e00007. doi: 10.14309/ctg.00000000007.
  44. Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Worns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 HCV Infections and Compensated Liver Disease. Clin Infect Diseases, 2019 Nov (10): 1657-1664.
  45. Wiles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retretment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 May;70(5): 1019-1023.
  46. Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar RW, Everson G, Phillips RW, Siddique A, Sullivan JG, Pilot-Matias T, Abunimeh M, Cohen DE, Younes Z. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral theapy. J Med Virol. 2019 Jul; 91(7): 1307-1312. Doi: 10.1002/jmv.25448.
  47. Lawitz E, Poordad F., Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat. 2019 Jun; 26(6): 675-684. doi: 10.1111/jvh.13079.
  48. Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: A Phase III study (ALLY-3C). Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print]
  49. Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, McHutchison JG, Subramanian GM, Myers RP, Middleton MS, Sirlin C, Loomba R, Nyangau E, Fitch M, Li K, Hellerstein M. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991
  50. Alkhouri N, Poordad F, Lawitz E. Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. Hepatol Commun. 2018 Jun 7;2(7):778-785
  51. Singh A, Fritze D, Mansouri M, Lopez R, Poordad F, Lawitz E, Cigarroa F, Halff G, Alkhouri N. Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis (PBC) in Young patients: Analysis of the United Network for Organ Sharing Database. Transplantation. 2018 Oct 30. doi: 10.1097/TP.0000000000002501. [Epub ahead of print]
  52. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan 25;378(4):354-369.
  53. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa F. Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print]
  54. Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017 Nov 6; 37:107-111. doi: 10.1016/j.coph.2017.10.001. [Epub ahead of print].
  55. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print]
  56. Feld JJ, Pawlotsky JM, Tatsch F, Sulkowski M, Poordad F, Jacobson I. Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment. Liver Int. 2017 Nov;37(11):1743-1744. doi: 10.1111/liv.13567.
  57. Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – a pooled analysis. J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083-4. doi: 10.1016/j.jhep.2017.06.011. [Epub ahead of print]
  58. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 3;5(4):371-375.
  59. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print]
  60. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print]
  61. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130. [Epub ahead of print]
  62. Poordad F. Diagnosis, Treatment, and Monitoring of Patients with Primary Biliary Cholangitis. Gastroenterol Hepatol (NY). 2016 Sep;12(9):561-564.
  63. Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645. [Epub ahead of print]
  64. Poordad F. Treatment of Hepatitis C Virus Genotype 3 Infection. Gastroenterol Hepatol (N Y). 2015;11(10):715-7.
  65. Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. Antimicrob Agents Chemother. 2016;60(10):6207-15. doi: 10.1128/AAC.00808-16. Print 2016 Oct.
  66. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Liver Int. 2016 Jul 30. doi: 10.1111/liv.13212. [Epub ahead of print] Liver Int. 2016. doi: 10.1111/liv.13212. [Epub ahead of print]
  67. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016. pii: S0016-5085(16)34816-8.
  68. Lawitz E, Poordad F, Hyland RH, Wang J, Liu L, Dvory-Sobol H, Brainard DM, McHutchison JG, Gutierrez JA. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. Antivir Ther. 2016 Jun 27. doi: 10.3851/IMP3062. [Epub ahead of print]
  69. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016 May;150(5):1147-1159
  70. Gutierrez JA, Landaverde C, Wells JT, Poordad F. Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient. Hepatology. 2016 Mar 17. doi: 10.1002/hep.28556. [Epub ahead of print]
  71. Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J. High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection. Liver Int. 2016 Jan 18. doi: 10.1111/liv.13067. [Epub ahead of print]
  72. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection with Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446. [Epub ahead of print]
  73. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks. J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676-5.
  74. Poordad F. Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician. Clin Liver Dis. 2015;19(4): ix-x. doi: 10.1016/j.cld.2015.08.001.
  75. Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S. The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therap Adv Gastroenterol. 2015;8(5):263-9.
  76. Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int. 2015;35(11):2358-62.
  77. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(11):861-70.
  78. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313(17):1728-35.
  79. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313(17):1736-44.
  80. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015:1-27.
  81. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low Relapse Rate Leads to High Concordance of SVR12 with SVR24 After Treatment with ABT-450/r, Ombitasvir, Dasabuvir Plus Ribavirin in Subjects with Chronic HCV Genotype 1 Infection in the AVIATOR Study. Clin Infect Dis. Clin Infect Dis. 2015;60(4):608-10
  82. Manns MP, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepat. 2015;22(4):366-75.
  83. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75
  84. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70(2):197-205
  85. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414-26
  86. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. J Hepatol. 2014;61(2):200-9
  87. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9.
  88. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. N Engl J Med. 2014 May 15;370(20):1879-88.
  89. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93.
  90. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study Group.N Engl J Med. 2014 Jan 16;370(3):211-21.
  91. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Jun 15;381(9883):2100-7.
  92. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Tarek Al-Assi M, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. N Engl J Med. 2013 May 16; 368 (20):1867-77.
  93. Treatment of HCV Infection by Targeting MicroRNA Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, Van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR.N Engl J Med. 2013 May 2; 368(18):1685-94.
  94. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Silva-Tillmann BD, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370(21):1973-82.
  95. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, Dasilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1604-14.
  96. Terrault N, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients. Am J Transplant. 2014;14(5):1129-35.
  97. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients with Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology. 2015;148(1):263
  98. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32
  99. Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: Results of the IDEAL study. Clin Infect Dis. 2014;58(7):960-9.
  100. Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission from Overt Hepatic Encephalopathy. Clin Clin Gastroenterol Hepatol. 2014;12(8):1390-7.
  101. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP. Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response. J Hepatol. 2014;60(4):748-56.
  102. Lawitz E, Poordad FF, Pang P, Hyland R, Ding X, Mo H, Symonds W, McHutchison J, Membreno F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-23.
  103. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients with HCV Genotype-1 Infection: a Phase IIb Trial. Gastroenterology. 2014;146(2):430-41.
  104. Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response. J Clin Gastroenterol. 2014;48(5):435-43.
  105. Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 2014;146(2):442-52.
  106. Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014;34(5):707-19.
  107. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson D, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 2013;145(5):1035-1044.
  108. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Pirathvisuth T, Marcellin P, Fried MW. A Global View of Hepatitis C: Physician Knowledge, Opinions, and Perceived Barriers to Care. Hepatology. 2013 Apr; 57(4): 1325-32. Doi: 10.1002/hep.26246.
  109. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013;58(6):1918-29.
  110. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ. Analysis of boceprevir rsistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013;444(1-2):329-36.
  111. Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther. 2013 Jul;38(1):16-27
  112. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013;13(1):190.
  113. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8.
  114. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. A randomized trial of emtricitabine/ tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal post-liver transplant. Liver Transpl. 2013;19(6):594-601.
  115. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein A Phase 2a Trial of 12-Week Interferon-Free Therapy with Two Direct-Acting Antivirals (ABT-450/r, ABT-072) and Ribavirin in IL28B C/C Patients with Chronic Hepatitis C Genotype 1. J Hepatol. 2013;59(1):18-23.
  116. Lalezari J, Box T, O’Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. IDX184 in combination with peginterferon alfa-2a and ribavirin for two weeks in treatment-naive patients with chronic hepatitis C. Antivir Ther. 2013;18(6):755-64.
  117. Poordad F, Lawitz E, Kowdley K, Cohen D, Podsacki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013;368:45-53
  118. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Efficacy and Safety of Boceprevir plus Peginterferon-Ribavirin in Patients with HCV G1 Infection and Advanced Fibrosis/Cirrhosis. J Hepatol. 2013;58(3):479-87.
  119. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir. Analysis from the SPRINT-2 trial. Hepatology. 2013;57(3):974-84.
  120. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F. Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clin Gastroenterol Hepatol. 2013;11(1):81-87
  121. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors That Predict Response of Patients with Hepatitis C Virus Infection to Boceprevir. Gastroenterology. 2012;143(3):608-618.
  122. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee P, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.N Engl J Med. 2012 Jan 19; 366(3):216-24.
  123. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716-24.
  124. Poordad F, Dieterich D. Treating Hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19: 449–464
  125. Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, Dinubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin. Hepatology. 2012 Aug;56(2):567-75
  126. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19(7):449-64.
  127. Khungar V, Poordad F. Hepatic Encephalopathy. Clin Liver Dis. 2012 May;16(2):301-20.
  128. Jacobson IM, Poordad F, Brown Jr RS, Kwo PY, Reddy KR, Schiff E. Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepat. 2012;19(4):236-243
  129. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Michael Millis J, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG; for the HIV-TR Investigators. Outcomes in liver transplantation in HIV/HCV coinfected recipients. Liver Transpl. 2012;18(6):716-26
  130. Khungar V, Poordad F. Management of over hepatic encephalopathy. Clin Liver Dis. 2012;16(1):73-89
  131. Poordad F, Chee GM. Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. Curr Gastroenterol Rep. 2012;14(1):74-7
  132. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-46.
  133. Poordad F, Theodore D, Sullivan J, Grotzinger K. Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients. J Med Econ. 2012;15(1):112-24
  134. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11): 1014-24.
  135. Telaprevir for retreatment of HCV infection. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.
  136. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):853-61.
  137. Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, Fair JH, Klein AS, Boland B, Colquhoun SD. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011;13(9):626-32.
  138. Khungar V, Poordad F. Emerging Therapeutic Options in Hepatitis C Virus Infection. Am J Manag Care. 2011;17: S123-130
  139. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012 Feb;56(2):313-9.
  140. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
  141. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.
  142. Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R. Boceprevir for Treatment of Chronic Hepatitis C Genotype 1 Nonresponders. N Engl J Med. 2011; 364:1207-1217.
  143. Poordad F; McCone J; Bacon B; Bruno S; Manns M; Sulkowski M; Jacobson I; Reddy R; Boparai N; Sniukien V; Brass C; Albrecht JK; Bronowicki JP for the SPRINT-2 Investigators. Boceprevir with Peginterferon and Ribavirin for Chronic Hepatitis C. N Engl J Med. 2011;364:1195-1206.
  144. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical Resource Utilization and Healthcare Costs in Patients with Chronic Hepatitis C Viral Infection and Thrombocytopenia. J Med Econ. 2011;14(2):194-206
  145. Poordad F. Big Changes are Coming in Hepatitis C. Curr Gastroenterol Rep. 2011;13(1):72-7
  146. Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010;52(6):1906-1914
  147. Yamini D, Basseri B, Chee GM, Arakelyan A, Enayati P, Tran TT, Poordad F. Tobacco and other factors have a negative impact on quality of life in hepatitis C patients. J Viral Hepat. 2011;18(10):714-20
  148. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL study team. Hepatitis C Virus Treatment-Related Anemia is Associated with Higher Sustained Virologic Response Rate. Gastroenterology. 2010; 139(5):1602-11
  149. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators.Lancet. 2010 Aug 28;376(9742):705-16.
  150. Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52(4):1208-15
  151. Zeuzem S, Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Curr Med Res Opin. 2010;26(7):1733-43.
  152. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81.
  153. Poordad F, Chee GM. Viral resistance in hepatitis B: prevalence and management. Curr Gastroenterol Rep. 2010;12(1):62-9
  154. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30(7):1012-8.
  155. Nissen NN, Geller SA, Klein A, Colquhoun S, Yamini D, Tran TT, Weinberg B, Winn J, Poordad F. Percutaneous liver biopsy after living donor liver transplantation resulting in fulminant hepatic failure: the first reported case of hepatic compartment syndrome. Transplant. 2010; 2010:273578.
  156. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients. Gastroenterology. 2010;139(1):120-9.
  157. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139(4):1257-66
  158. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292-303
  159. Poordad FF. The role of rapid virologic response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther. 2010;31(12):1251-67.
  160. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carriho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;5(12);422-30
  161. Poordad F, Zeldin G, Harris SI, Ke J, Xu L, Mayers D, Zhou XJ. Absence of Effect of Telbivudine on Cardiac Repolarization: Results of a Thorough QT/QTc Study in Healthy Participants. J Clin Pharmacol. 2009;49(12):1436-46
  162. Poordad FF, Chee G. Tarabivirin; a potential alternative to ribavirin. Future Virology 2009;4(2):113-120.
  163. Tran T, Rakoski M, Martin P, Poordad F. Screening for hep B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther. 2009;31(2):240-6
  164. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. N Engl J Med. 2009 Aug 6;361(6):580-93.
  165. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination (METRO) study group. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009;50(6):1719-26
  166. Poordad FF, Flamm SL. Virological relapse in chronic hepatitis C. Antivir Ther. 2009;14(3):303-13.
  167. Poordad F, Sigal S, Brown RB. Pathophysiologic Basis for the Medical Management of Portal Hypertension. Expert Opinion in Pharmacotherapy. Expert Opin Pharmacother. 2009;10(3):453-67.
  168. Poordad F, Landaverde C. Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts SVR and relapse in Genotype 1. Therapeutic Advances in Gastroenterology. 2009; 2:91-97
  169. Poordad F, Reau N. Viral-guided hepatitis C therapy. Current Hepatitis Reports. 2009;8(2):66-72.
  170. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009;17(1):16-22
  171. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6);580-93.
  172. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18);1827-38.
  173. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; EPIC Study Group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136(5):1618-28.
  174. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28(5):503-22
  175. Afdhal N, McHutchison J, Brown R, Jacobson I, Manss M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48(6):1000-7
  176. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008;146(1):78-84.
  177. Carr C, Blaine Hollinger F, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG.Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver Int. 2007;27(8):1111-8.
  178. Poordad FF, Khatibi B, Tran TT. Analysis of HCV Therapies and Algorithms: where we are now and the near future. Hepatology Reviews 2007;4(1):3-8.
  179. Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT. Hepatotoxicity of 6-Mercaptopurine (6-MP) and Azathioprine (AZA) in Adult IBD Patients. Am J Gastroenterol. 2007
  180. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9.
  181. Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, Geller SA, Vierling JM, Martin, P. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006;21(2):381-3.
  182. Poordad FF. Nonalcoholic fatty liver disease: a review. Expert Opin Emerg Drugs. 2005;10(3):661-70.
  183. Shackleton CR, Vierling JM, Nissen N, Martin P, Poordad F, Tran T, Colquhoun SD. Morbidity in live liver donors: standards-based adverse event reporting further refined. Arch Surg. 2005;140(9):888-95; discussion 895-6.
  184. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm. 2005;11(8):687-94.
  185. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005;39(1):75-7
  186. Tran T, Nissen, N, Poordad F, Martin P. Advances in Liver Transplantation. Postgraduate Medicine 2004;115(5):73-85.
  187. Papadakis KA, Matuk R, Abreu MT, Vasiliauskas EA, Fleshner PR, Lechago J, Tran T, Poordad FF, Martin P, Vierling J, Targan SR. Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease. Gut. 2004;53(9):1389-90.
  188. Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicrosopic fibrosis associated with 6-thiguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004; 28:1204-1211
  189. Firpi R, Tran T, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced Hyperlipidemia in Liver Transplant Recipients is not Dose Dependent. Aliment Pharmacol Ther. 2004 May 1;19(9):1033-9.
  190. Poordad F, Gish RB, Wakil E, Martin, PM, Yao F. De novo Non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J of Transplantation 2003; 3:1413-1417.
  191. Shastri S, Dubinsky M, Poordad FF, Vasiliauskas EA, Geller SA. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med. 2004; 128:49-53
  192. Poordad FF. IDN-6556. Curr Opin Investig Drugs. 2004;5(11):1198-204
  193. Poordad FF, Fabrizi F, Martin P. Hepatitis C Infection Associated with Renal Disease and Chronic Renal Failure. Semin Liver Dis 2004;24 Suppl 2:69-77.
  194. Poordad FF. FIBROSpect II: A potential non-invasive test to assess hepatic fibrosis. Expert Rev. Mol. Diagn. 2004; 4(5): 89-93
  195. Nissen NN, Cavazzoni E, Tran TT, Poordad FF. Emerging role of transplantation for primary liver cancers. Cancer J. 2004;10(2):88-96.
  196. Poordad FF. Transplantation and Recurrent Hepatitis B. Clinics in Liver Disease 2004;8(2): 461-473.
  197. Dubinsky M, Vasiliaskas EA, Singh H, Abreu MT, Papadakis K, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine (6-TG) can cause serious liver injury in inflammatory bowel disease (IBD) patients. Gastroenterology 2003 Aug;125(2):298-303
  198. Fabrizi F, Lunghi G, Poordad F, Martin P. Peritoneal dialysis and infection by hepatitis B and C virus. Int J Artif Organs. 2003 Apr;26(4):278-88.
  199. Poordad FF, Tran T, Martin P. Developments in hepatitis C therapy during 2000-2002. Expert Opin Emerg Drugs. 2003;8(1):9-25.
  200. Tran T, Poordad FF, Martin P. Chronic Hepatitis C. Current Hepatitis Reports 2003; 2 (1) 3-8.
  201. Tran T, Poordad F, Martin P. Hepatocellular Carcinoma. Clinical Perspectives in Gastroenterology, 2002;5(5):302-306.
  202. Fabrizi F, Lunghi G, Poordad F, Martin P. Genetic variability of hepatitis C virus in dialysis: the implications. Int J Artif Organs. 2002 Nov;25(11):1034-48.
  203. Fabrizi F, Lunghi G, Martin P, Poordad F. Serological and molecular testing in hepatitis B and the dialysis patient. Int J Artif Organs. 2002 Feb;25(2):91-9.
  204. Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002 Jul;36(1):3-10.
  205. Fabrizi F, Lunghi G, Poordad F, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol. 2002 Mar-Apr;15(2):113-22.
  206. Fabrizi F, Lunghi G, Poordad F, Martin P. Novel perspectives on hepatitis B vaccine in dialysis population. Int J Artif Organs. 2002 Mar;25(3):174-81
  207. Fabrizi F, Poordad F, Martin, P. Diagnostic workup of hepatitis C and the patient on maintenance dialysis. Int J Artif Organs. 2001 Dec; 24(12): 843-52.
  208. Tan H, Markowitz J…Poordad F, et al. Liver Transplantation in Patients with Severe Portopulmonary Hypertension Treated with Preoperative Chronic Intravenous Epoprostenol. Liver Transplantation. 2001;7(8):745-9.
  209. Tan H, Dumbler S, Maley W, Klein A, Burdick J, Poordad F, Thuluvath P, Markowitz J. Human Monocytic Ehrilichiosis: An Emerging Pathogen in Transplantation. Transplantation 2001;71(11):1678-80.
  210. Poordad FF, Gish RG. Developments in Hepatitis C During 1997-1999. Exp. Opin. Invest. Drugs 1999;8(9):1249-1262
  211. Poordad FF, Gish RG. Evolving Therapies for the Treatment of Viral Hepatitis. Emerging Drugs, Vol 4,1999, London, UK: Ashley Publications Ltd.,1999;4:15-34.
  212. Yao F, Osorio R, Roberts J, Poordad FF, Briceno M, Gish RG. Intramuscular (IM) Hepatitis B Immune Globulin (HBIG) Combined with Lamivudine for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Liver Transpl Surg 1999 Nov;5(6):491-6.
  213. Sokoll L, Levine M, Kroll M, Poordad F, Chan D. Bone to Total Alkaline Phosphatase Ratios Improve Sensitivity and Specificity of Bone Alkaline Phosphatase Immunoassays. Clinical Biochemistry 1997; 30:625-629
  214. Whittier F, Aldir R, Jarjoura D, Poordad F, et al. Practicing and Resident Physicians’ Views on Pharmaceutical Companies. J of Continuing Education in the Health Professions 1996; 16:25-32